PA8800301A1 - Productos quimioterapeuticos cristalinos - Google Patents

Productos quimioterapeuticos cristalinos

Info

Publication number
PA8800301A1
PA8800301A1 PA20088800301A PA8800301A PA8800301A1 PA 8800301 A1 PA8800301 A1 PA 8800301A1 PA 20088800301 A PA20088800301 A PA 20088800301A PA 8800301 A PA8800301 A PA 8800301A PA 8800301 A1 PA8800301 A1 PA 8800301A1
Authority
PA
Panama
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
1hindazol
Prior art date
Application number
PA20088800301A
Other languages
English (en)
Inventor
F Henry Rodger
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40174825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8800301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PA8800301A1 publication Critical patent/PA8800301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

FORMA CRISTALINA 1 DE ETANOLATO DE N-[4-(3-AMINO-1HINDAZOL-4-IL)FENIL]-N'-(2-FLUORO-5-METILFENIL)UREA·1/4, FORMAS DE ELABORARLA, FORMULACIONES QUE LA COMPRENDEN Y ELABORADAS CON LA MISMA Y MÈTODOS QUE LA UTILIZAN PARA EL TRATAMIENTO DE PACIENTES ENFERMOS.
PA20088800301A 2007-10-19 2008-10-17 Productos quimioterapeuticos cristalinos PA8800301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98131007P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
PA8800301A1 true PA8800301A1 (es) 2009-08-26

Family

ID=40174825

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088800301A PA8800301A1 (es) 2007-10-19 2008-10-17 Productos quimioterapeuticos cristalinos

Country Status (25)

Country Link
US (1) US7994208B2 (es)
EP (1) EP2195300B1 (es)
JP (2) JP5878689B2 (es)
KR (1) KR20100085986A (es)
CN (1) CN101827821B (es)
AR (1) AR068918A1 (es)
AU (1) AU2008312528A1 (es)
BR (1) BRPI0818067A2 (es)
CA (1) CA2699302C (es)
CL (1) CL2008003091A1 (es)
CO (1) CO6280482A2 (es)
CR (1) CR11387A (es)
DO (1) DOP2010000113A (es)
EC (1) ECSP10010182A (es)
ES (1) ES2547878T3 (es)
GT (1) GT201000093A (es)
MX (1) MX2010004288A (es)
PA (1) PA8800301A1 (es)
PE (1) PE20091075A1 (es)
RU (1) RU2010119927A (es)
TW (1) TW200932728A (es)
UA (1) UA99747C2 (es)
UY (1) UY31408A1 (es)
WO (1) WO2009052225A1 (es)
ZA (1) ZA201002180B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic
US20140212355A1 (en) * 2013-01-28 2014-07-31 Abbott Cardiovascular Systems Inc. Trans-arterial drug delivery
JP7346916B2 (ja) * 2019-06-04 2023-09-20 京セラドキュメントソリューションズ株式会社 緩衝構造体およびそれを備えた包装材

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
ATE469888T1 (de) * 2003-05-22 2010-06-15 Abbott Lab Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
US20070104780A1 (en) 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
JP2010509289A (ja) * 2006-11-09 2010-03-25 アボット ゲーエムベーハー ウント コンパニー カーゲー チロシンキナーゼ阻害剤の経口投与用薬学的剤形
US7994208B2 (en) * 2007-10-19 2011-08-09 Abbott Laboratories Crystalline chemotherapeutic

Also Published As

Publication number Publication date
PE20091075A1 (es) 2009-08-27
CR11387A (es) 2010-08-18
UA99747C2 (en) 2012-09-25
CO6280482A2 (es) 2011-05-20
MX2010004288A (es) 2010-04-30
US20090105326A1 (en) 2009-04-23
US7994208B2 (en) 2011-08-09
TW200932728A (en) 2009-08-01
CA2699302C (en) 2016-06-21
EP2195300A1 (en) 2010-06-16
BRPI0818067A2 (pt) 2015-03-31
WO2009052225A1 (en) 2009-04-23
EP2195300B1 (en) 2015-06-24
CL2008003091A1 (es) 2009-09-04
ECSP10010182A (es) 2010-06-29
RU2010119927A (ru) 2011-11-27
JP5878689B2 (ja) 2016-03-08
KR20100085986A (ko) 2010-07-29
AU2008312528A1 (en) 2009-04-23
AR068918A1 (es) 2009-12-16
ZA201002180B (en) 2011-10-26
UY31408A1 (es) 2009-05-29
CN101827821B (zh) 2012-09-05
GT201000093A (es) 2012-03-12
DOP2010000113A (es) 2010-07-31
CN101827821A (zh) 2010-09-08
CA2699302A1 (en) 2009-04-23
JP2011500704A (ja) 2011-01-06
ES2547878T3 (es) 2015-10-09
JP2015042650A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
CL2008002247A1 (es) Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros.
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
PA8800301A1 (es) Productos quimioterapeuticos cristalinos
DOP2010000112A (es) Productos quimioterapeuticos cristalinos
DOP2010000111A (es) Productos quimioterapeuticos cristalinos
DOP2010000116A (es) Productos quimioterapeuticos cristalinos
GT200600141A (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares
PA8800201A1 (es) Productos quimioterapéuticos cristalinos
CL2009000496A1 (es) Formas cristalina tipo iii de (3,5-bis trifluorometil)-n-[4-metil-3-(4-piridin-3-il)-pirimidin-2-ilamino)-fenil]-benzamida; proceso de preparacion de la forma cristalina iii; composion farmaceutica que compende la forma cristalina iii; y su uso como agente antitumoral.
AR063895A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de la leucomalacia periventricular
RS54325B1 (en) PHARMACEUTICAL COMPOUNDS CONTAINING BETA GALACTOSIDASE AND ALPHA GALACTOSIDASE AND THEIR USE FOR THE TREATMENT OF GASTROESOFAGEAL REFLUX DISEASE
CU20070232A7 (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento de los trastornos bipolares